HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%

Stock News

01/05

MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.

The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.

Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.

Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.

Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.

CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.

Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.

Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1185164871"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185164871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185164871?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185164871","market":"us","top_or_hot":-1,"title":"HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%","media":"Stock News","content":"<p>MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.</p>\n<p>The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.</p>\n<p>Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.</p>\n<p>Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.</p>\n<p>Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.</p>\n<p>CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.</p>\n<p>Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.</p>\n<p>Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | MP CARDIOFLOW-B (02160) Surges Over 10% Again, Full-Year TAVI Product Implants Soar Nearly 350%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-05 14:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.</p>\n<p>The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.</p>\n<p>Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.</p>\n<p>Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.</p>\n<p>Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.</p>\n<p>CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.</p>\n<p>Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.</p>\n<p>Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"醫療保健設備","start_time":0,"source_url":"","article_id":"1185164871","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185164871","pubTimestamp":1767593193,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million. The company recently announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","TAVI":"Tavia Acquisition Corp","BK1574":"生物医药B类股","02160":"微创心通-B-新","BK1583":"高瓴概念"},"translate_title":"港股动向|MP心通-B(02160)再升超10%全年TAVI产品植入物飙升近350%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAVI":1,"02160":1},"content_text":"MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.\nThe company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.\nSpecifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.\nFurthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.\nNotably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.\nCITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.\nConcurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.\nLooking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}